Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities. The two companies have a long-standing relationship.
Thermo Fisher Scientific acquired Core Informatics in March 2017 and underwent its integration into TMO’s new Digital Science division.
Sema4 is a health information company that spun out of the Mount Sinai Health System in June 2017. The Mount Sinai Health System is a network of hospitals comprising an integrated healthcare system.
The bulk of Sema4’s laboratory business is in reproductive genomics, which includes newborn screening. The company has been stepping up its laboratory business in the field of oncology as well.
After the spin-off, Sema4 entered into several strategic partnerships, including the partnership with Alexion (ALXN) and GNS Healthcare in rare disease diagnosis and therapeutic discovery.
Abbott Laboratories (ABT) and Agilent Technologies (A) are two of the major companies that offer products and solutions in the genomics space. The SPDR S&P 500 ETF (SPY) holds ~0.33% of its portfolio in Thermo Fisher Scientific.
Platform for Science
Core Informatics’ Platform for Science is a lab informatics solution that offers access to Core’s LIMS, scientific data management system, electronic laboratory notebook, and collaborations products. It also includes access to the company’s next-generation sequencing, biobanking, quality control, and analysis scientific applications.
According to Jamie Coffin, president and chief operating officer of Sema4 Genomics, “As we transition from being a more academic-type lab into a commercial lab, being able to track all our materials much more effectively is incredibly important.
“Over the last year, the team has been evaluating a lot of different LIMS across the marketplace and we settled on working with Core, mostly because of a longstanding relationship we’ve had with Thermo Fisher and their real strong experience in the genomics space.”